Risk factors for hospital-acquired pneumonia caused by imipenem-resistant Pseudomonas aeruginosa in an intensive care unit

Anaesthesia and Intensive Care

Volumn 38, Issue 6, 2010, Pages 994-1001

  Furtado, G H ^a   Gales, A C ^a   Perdiz, L B ^a   Santos, A F ^a,b   Wey, S B ^a   Medeiros, E A ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Alerta Laboratory

Author keywords

Hospital acquired pneumonia; Intensive care; Pseudomonas aeruginosa; Risk factors

Indexed keywords

AMINOGLYCOSIDE; CARBAPENEM; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ACUTE PHYSIOLOGIC AND CHRONIC HEALTH EVALUATION II; ADULT; ARTICLE; BACTERIAL STRAIN; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; FEMALE; HEMODIALYSIS PATIENT; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; IMIPENEM RESISTANT PSEUDOMONAS AERUGINOSA; INFECTION RISK; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; UNIVERSITY HOSPITAL;

EID: 78650448696     PISSN: 0310057X     EISSN: 14480271     Source Type: Journal    
DOI: 10.1177/0310057x1003800605     Document Type: Article

References (35)

1. Paramythiotou E, Lucet J-C, Timsit J-F, Vanjak D, Paugam-Burtz C, Trouillet J-L et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis 2004; 38:670-677.
2. Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32:S146-155.
3. Harris AD, Smith D, Johnson JA, Bradham DD, Roghmann M-C. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 2002; 34:340-345.
4. El Amari EB, Chamot E, Auckenthaler R, Pechere JC, Van Delden C. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 2001; 33:1859-1864.
5. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470-85.
6. Furtado GHC, Martins ST, Machado AMO, Wey SB, Medeiros EAS. Clinical culture surveillance of carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter species in a teaching hospital in Sao Paulo, Brazil: a 7-year study. Infect Control Hosp Epidemiol 2006; 27:1270-1273.
7. Harris AD, Karchmer TB, Carmeli Y, Samore MH. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 2001; 32:1055-1061. (Pubitemid 32299641)
8. Kaye KS, Harris AD, Samore M, Carmeli Y. The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol 2005; 26:346-351. (Pubitemid 40545579)
9. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16:128-140.
10. McCabe WR, Jackson GG. Treatment of pyelonephritis: bacterial, drug and host factors in success or failure among 252 patients. N Engl J Med 1965; 272:137-144.
11. Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard, 7th ed. Wayne, PA 2006. M7-A7.
12. Troillet N, Samore MH, Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997; 25:1094-1098.
13. Zavascki AP, Cruz RP, Goldani LZ. Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparative analysis of two case-control studies in hospitalized patients. J Hosp Infect 2005; 59:96-101.
14. Ozkurt Z, Ertek M, Erol S, Altoparlak U, Akcay MN. The risk factors for acquisition of imipenem-resistant Pseudomonas aeruginosa in the burn unit. Burns 2005; 31:870-873.
15. Fortaleza CM, Freire MP, Filho Dde C, de Carvalho Ramos M. Risk factors for recovery of imipenem- or ceftazidime-resistant Pseudomonas aeruginosa among patients admitted to a teaching hospital in Brazil. Infect Control Hosp Epidemiol 2006; 27:901-906.
16. Falagas ME, Koletsi PK, Kopterides P, Michalopoulos A. Risk factors for isolation of strains susceptible only to polymyxin among patients with Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2006; 50:2541-2543.
17. Tam VH, Chang K-T, LaRocco MT, Schilling AN, McCauley SK, Poole K et al. Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2007; 58:309-314. (Pubitemid 47017651)
18. Pena C, Guzman A, Suarez C, Dominguez MA, Tubau F, Pujol M et al. Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients. Antimicrob Agents Chemother 2007; 51:1967-1971.
19. Defez C, Fabbro-Peray P, Bouziges N, Gouby A, Mahamat A, Daures JP et al. Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. J Hosp Infect 2004; 57:209-216.
20. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006; 27:893-900.
21. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006; 50:43-48.
22. Cao B, Wang H, Sun H, Zhu Y, Chen M. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infect 2004; 57:112-118.
23. Leroy O, d'Escrivan T, Devos P, Dubreuil L, Kipnis E, Georges H. Hospital-acquired pneumonia in critically ill patients: factors associated with episodes due to imipenem-resistant organisms. Infection 2005; 33:129-135.
24. Mentzelopoulos SD, Pratikaki M, Platsouka E, Kraniotaki H, Zervakis D, Koutsoukou A et al. Prolonged use of carbapenems and colistin predisposes to ventilator-associated pneumonia by pandrug-resistant Pseudomonas aeruginosa. Intensive Care Med 2007; 33:1524-1532.
25. Lodise TP Jr, Miller C, Patel N, Graves J, McNutt L-A. Identification of patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk of infection with carbapenem-resistant isolates. Infect Control Hosp Epidemiol 2007; 28:959-965.
26. Satake S, Yoneyama H, Nakae T. Role of OmpD2 and chromosomal beta-lactamase in carbapenem resistance in clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother 1991; 28:199-207.
27. Neu HC. Resistance of Pseudomonas aeruginosa to imipenem. Infect Control Hosp Epidemiol 1992; 13:7-9.
28. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358:111-124.
29. Sprung CL, Caralis PV, Marcial EH, Pierce M, Gelbard MA, Long WM et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med 1984; 311:1137-1143.
30. Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MA et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995; 23:1430-1439.
31. Kube D, Sontich U, Fletcher D, Davis PB. Proinflammatory cytokine responses to P. aeruginosa infection in human airway epithelial cell lines. Am J Physiol Lung Cell Mol Physiol 2001; 280:L493-502.
32. Fukushima K, Ando M, Suga M, Araki S. Impaired function of polymorphonuclear leukocytes exuded into bronchoalveolar spaces infected with Pseudomonas aeruginosa in steroid-treated rabbits. Exp Lung Res 1987; 13:141-155.
33. Sayer HG, Longton G, Bowden R, Pepe M, Storb R. Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention. Blood 1994; 84:1328-1332. (Pubitemid 24245903)
34. Pifarre R, Falguera M, Vicente-de-Vera C, Nogues A. Characteristics of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. Respir Med 2007; 101:2139-2144. (Pubitemid 47324242)
35. Sader HS, Reis AO, Silbert S, Gales AC. IMPs, VIMs and SPMs: the diversity of metallo-beta-lactamases produced by carbapenem-resistant Pseudomonas aeruginosa in a Brazilian hospital. Clin Microbiol Infect 2005; 11:73-76.